ONCE-DAILY QELBREE VILOXAZINE EXTENDED-RELEASE CAPSULES 100 MG 150 MG 200 MG
Dead / Abandoned — Abandoned — no statement of use filed (as of 29 Aug 2022)
What this means for you
This application is over — abandoned 29 Aug 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90287810
- Mark type
- Design + words
- Filed
- 29 Oct 2020
- Published for opposition
- 01 Jun 2021
- Abandoned
- 29 Aug 2022
- Attorney of record
- Mark Simpson
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for therapeutic use in humans, namely, for the treatment and prevention of central nervous system and peripheral nervous system diseases and disorders, psychiatric and neurological diseases and disorders; all containing Viloxazine
Owner
- Supernus Pharmaceuticals, Inc., Rockville, MD, US
- Supernus Pharmaceuticals, Inc., Rockville, MD, US
Prosecution history
- 29 Aug 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 29 Aug 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 29 Jan 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Jan 2022 — SOU EXTENSION 1 GRANTED
- 27 Jan 2022 — SOU EXTENSION 1 FILED
- 27 Jan 2022 — SOU TEAS EXTENSION RECEIVED
- 27 Jul 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Jun 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Jun 2021 — PUBLISHED FOR OPPOSITION
- 12 May 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 28 Apr 2021 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 28 Apr 2021 — ASSIGNED TO LIE
- 28 Apr 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Apr 2021 — EXAMINER'S AMENDMENT ENTERED
- 27 Apr 2021 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED